NBIX - Neurocrine Biosciences Non-GAAP EPS of $1.25 beats by $0.13 revenue of $452.7M beats by $4.72M
2023-08-01 07:18:53 ET
- Neurocrine Biosciences press release ( NASDAQ: NBIX ): Q2 Non-GAAP EPS of $1.25 beats by $0.13 .
- Revenue of $452.7M (+19.7% Y/Y) beats by $4.72M .
-
INGREZZA (valbenazine) Second Quarter Net Product Sales of $440 Million Representing 26% Year-Over-Year Growth
-
INGREZZA (valbenazine) 2023 Net Product Sales Guidance Raised to $1.77 - $1.82 Billion
For further details see:
Neurocrine Biosciences Non-GAAP EPS of $1.25 beats by $0.13, revenue of $452.7M beats by $4.72M